Another patent to be issued soon for this little virtual company......
Synthetic Blood International Inc. Announces U.S. Patent Office Allowance of Glucose Biosensor Patent Claims
Business Wire - February 16, 1999 09:57
KETTERING, Ohio--(BUSINESS WIRE)--Feb. 16, 1999--Synthetic Blood International Inc. (OTCBB:SYBD) announced today that the U.S. patent office has issued a notice allowing all claims in a new patent application covering the company's implantable glucose biosensor. The patent is expected to be issued soon.
The patent application, "Glucose Sensor," covers the company's proprietary glucose biosensor system. In particular, it protects the membrane-enzyme complex that regulates the availability of glucose which permits accurate measurement of glucose levels with low ambient oxygen tension.
"Intellectual property is the most important asset a biomedical research and development company such as ours can have," said Robert Nicora, president. "We are pleased to be able to add this important patent to the company's growing patent portfolio." The biosensor system is being developed for use in diabetic patients to continuously monitor blood glucose levels.
The patent is the fourth announced by SYBD in the past month.
SYBD is also developing Oxycyte(TM), a perfluorocarbon based blood substitute, and Fluorovent(TM), a perfluorocarbon liquid ventilation product.
Synthetic Blood International is located in Kettering, Ohio, with West Coast offices and laboratories in Newport Beach, Calif. The company's stock is traded on the OTC Electronic Bulletin Board, symbol SYBD. The company's Web site is sybd.com and e-mail address is sybd@siscom.net.
CONTACT: Synthetic Blood International Inc.
Joan Mahan, 800/809-6054 |
